Policy & Regulation
Ablexis Inks Licensing Agreement with Memorial Sloan Kettering Cancer Center
10 October 2018 - - US-based biopharmaceutical company Ablexis, LLC has inked a license agreement with Memorial Sloan Kettering Cancer Center, the company said.

The license grants Memorial Sloan Kettering rights to research, develop and commercialize, with rights to sub-license, certain AlivaMab antibodies against a specific target.

The antibodies were generated by the Tri-Institutional Therapeutics Discovery Institute, Inc. under a non-exclusive license of AlivaMab Mouse announced in January 2017.

Under this new license, Ablexis could receive clinical development and approval milestones and a running revenue share of sales of products derived from the AlivaMab antibodies.

The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies.

The platform has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics and CAR-Ts and for a range of applications including sequence diverse panels of mAbs, epitope diverse panels of mAbs, challenging targets such as GPCRs and challenging design goals such as IC50 values of very low picomolar.

Ablexis created and commercialises the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery.

The company has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities.

Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses.